News
About LockeT Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and ...
Cube Biotech, a pioneer in membrane protein stabilization and purification, and X-Chem, the global leader in DNA-Encoded Library (DEL) technology and data-driven drug discovery, are proud to announce ...
With this milestone, VG801 now holds RMAT, Rare Pediatric Disease, and Orphan Drug designations. VeonGen has also been selected to collaborate with the FDA under the Rare Disease Endpoint Advancement ...
WESTBROOK, Maine, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, is confirmed to present at the 2025 ...
One of the most heartwarming highlights was the iconic lemonade stand, staffed by patient families, which raised over $12,000 on the course. Guests enjoyed a perfect blend of fun and philanthropy, ...
Vafseo was approved by the U.S. Food and Drug Administration (FDA) in March 2024 for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months. The ...
Live webcasts and replays of the Cantor and H.C. Wainwright fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will ...
Valitor Announces Upcoming Presentations at the Ophthalmology Futures Retina Forum and Euretina Conference, Including New Data for its Long-Acting Anti-VEGF Drug Candidate for Wet AMD, VLTR-559 > ...
(Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 ...
L’ampleur et la complexité des opérations dépassent celles en réponse à la pandémie de COVID-19 ...
Chemomab Presentation at H.C. Wainwright 27th Annual Global Investment Conference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results